
    
      This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and
      Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD. Patients will receive one of
      four doses for up to four weeks. Single/multiple dose pharmacokinetics in these patients will
      be studied. At the end of four weeks, investigator will evaluate safety and tolerability and
      decide whether to continue treatment for a total of six months to further evaluate safety and
      preliminary efficacy.
    
  